Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Aug;25(8):889-94.
doi: 10.1111/j.1464-5491.2008.02514.x.

RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes

Affiliations
Free PMC article
Review

RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes

F M Gribble. Diabet Med. 2008 Aug.
Free PMC article

Abstract

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic beta-cells. Agents that either mimic GLP-1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance endogenous GLP-1 release are under assessment. As intestinal peptides have a range of actions, including appetite regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug development.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Glucose-dependent stimulation of insulin release by glucagon-like peptide-1 (GLP-1). At low glucose concentrations (left), intracellular [Ca2+] is low, and although stimulation by GLP-1 causes an increase in cyclic adenosine monophosphate (cAMP), this causes only small increases in [Ca2+] and minimal enhancement of insulin release (dashed arrows). The amount of insulin released is not enough to induce hypoglycaemia. At high glucose concentrations or in the presence of sulphonylureas (right), [Ca2+] is elevated, and the elevation of cAMP by GLP-1 can then potently enhance the rate of insulin release, as well as further increasing [Ca2+].
FIGURE 2
FIGURE 2
A working model of glucagon-like peptide-1 (GLP-1) release from the intestinal L-cell. Dietary nutrients stimulate GLP-1 release from intestinal L-cells, as a consequence of their Na+-coupled uptake and subsequent metabolism, which cause membrane depolarization (ΔΨ) and Ca2+ entry. Indirect signals from hormones and neurotransmitters can stimulate release by a variety of mechanisms, including elevation of cyclic adenosine monophosphate (cAMP) (which acts as both an initiator and an amplifier of GLP-1 release), and Ca2+ release from stores. GLP-1 released at the basolateral membrane stimulates insulin release from pancreatic β-cells and reduces appetite.

References

    1. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept. 2005;128:87–91. - PubMed
    1. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744. - PubMed
    1. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830. - PubMed
    1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705. - PubMed
    1. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA. 2007;104:943–948. - PMC - PubMed

Publication types

MeSH terms